期刊文献+

影响多囊卵巢综合征不孕患者治疗依从性的相关因素分析 被引量:10

Correlates of treatment compliance in infertile patients with polycystic ovary syndrome
原文传递
导出
摘要 目的 调查多囊卵巢综合征(PCOS)不孕患者治疗依从性的相关影响因素,为临床治疗、专科咨询及健康教育提供依据.方法 借鉴综合Morisky问卷及PCOS防治原则设计调查问卷,对白2009年3月到2010年9月到本院生殖中心门诊就诊的PCOS不孕患者共128例进行问卷调查,并对结果进行logistic回归分析.结果 除去不完整及随访脱落病例,最终120例纳入统计范围.经logistic回归分析显示纳入分析的患者中仅34.2%(41/120)依从性好,与PCOS不孕患者治疗依从性相关的因素有体重指数(OR=2.426,95% CI=1.428~4.121)、结婚时间(OR=0.398,95% CI=0.225~0.704)、担心药物不良反应(OR=0.216,95% CI=0.067~0.694)(P<0.05).结论 肥胖、结婚时间短及担心药物不良反应的PCOS不孕患者治疗依从性较低,临床上应加强对这部分人群的宣传及干预以提高PCOS依从性. Objective To investigate factors that correlated to compliance of treatment in infertile patients with polycystic ovary syndrome (PCOS) to provide basis for clinical treatment, specialist consultation and health education. Methods Compliance was assessed by a questionnaire designed by reference to Morisky-Green test and therapeutic principles for PCOS. Interviews were performed in 128 infertile patients with PCOS in Renmin Hospital of Wuhan University, Wuhan, Hubei in China during March 2009 to September 2010. Data were analyzed with logistic regression. Results Logistic regression analysis revealed that a total of 41 (34.2% ) of 120 participants investigated showed good compliance. Factors that might significantly (P 〈 0.05 ) correlate compliance of treatment included body mass index (BMI) of the patients ( OR = 2.426, 95% CI = 1.428 - 4.121 ), length of their marriage ( OR = 0.398, 95% CI =0.225 - 0.704) and their concerns for adverse drug reactions ( OR= 0.216, 95% CI = 0.067 - 0.694).Conclusions Patients with obesity, shorter length of marriage and concerns for adverse drug reactions show lower compliance. Publicity and intervention to those patients should be strengthened in clinics to improve their treatment compliance in patients with PCOS.
出处 《中华全科医师杂志》 2011年第3期166-170,共5页 Chinese Journal of General Practitioners
关键词 多囊卵巢综合征 不育 女(雌)性 病人依从 回归分析 Polycystic ovary syndrome Infertility, female Patient compliance Regression analysis
  • 相关文献

参考文献21

  • 1Schroder AK, Tauchert S, Ortmann O, et al. Insulin resistance in patients with polycystic ovary syndrome. Ann Med, 2004,36:426- 439.
  • 2Hart R, Hiekey M, Franks S. Definitions, prevalence and symptoms of polyeystic ovaries and polycystic ovary syndrome. Best Pratt Res Clin Obstet Gynaccol, 2004,18:671-683.
  • 3WHO. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003:323.
  • 4Gurwitz JH, Field TS, Harrold LR, et at. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA, 2003,289:1107-1116.
  • 5Morisky DE, Green LW, Levine DM. Concurrent and predictivevalidity of a self-reported measure of medication adherence. Med Care, 1986,24:67-74.
  • 6The Rotterdam ESHRE/ASRM - Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.
  • 7Fertil Steril, 2004,81 : 19-25. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab, 1961,21:1440-1447.
  • 8Hamilton GA. Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs, 2003,2:219-228.
  • 9Gambineri A, Pelusi C, Vicennati V, et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord, 2002, 26 : 883-896.
  • 10A1-Azemi M, Omu FE, Omu AE. The effect of obesity on the outcome of infertility management in women with polycystic ovary syndrome. Arch Gynecol Obstet, 2004,270:205-210.

二级参考文献15

  • 1Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrognic activity [J]. Ann N Y Acad Sci, 1995, 761: 311-335.
  • 2World Health Organization. Family Plannning-A global handbook for providers [M].2007, 21-22.
  • 3国家人口计生委科研所.激素避孕和HIV:新的发现,但政策维持不变[J].展望,2006,22:1-1.
  • 4Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev, 2009 : CD006586.
  • 5Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med, 2002, 346 : 2025 -2032.
  • 6Deligeoroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system cancer. Ann N Y Acad Sci, 2003,997: 199-208.
  • 7Braendle W, Kuhl H, Mueck A, et al. Does hormonal contraception increase the risk for tumors? Ther Umsch, 2009,66 : 129-135.
  • 8Keeling D. Combined oral contraceptives and the risk of myocardial infarction. Ann Med, 2003,35:413-418.
  • 9Bracken MB. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. Obstet Gynecal, 1990,76:552-557.
  • 10Bamhart KT, Schreiber CA. Return to fertility following discontinuation of oral contraceptives. Fertil Steril, 2009,91:659- 663.

共引文献55

同被引文献85

引证文献10

二级引证文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部